SELLAS Life Sciences Group, Inc. announced the completion of enrollment as well as positive initial data from the ongoing Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML). Key Highlights from the Initial Data: Safety: SLS009 was generally well-tolerated with no safety issues observed across all doses; There were no dose-limiting and no high-grade treatment-related non-hematologic toxicities. Hematologic toxicities profile was not different from that of venetoclax-based regimens alone; 27 patients had at least one efficacy assessment as of May 25, 2024, and were considered evaluable for efficacy.

Efficacy: The overall response rate was 29.6% in all evaluable patients, and across all SLS009 doses, with the highest response rate of 50% observed at the dosing regimen of 30 mg BIW; In the first dose level (safety level, one dose level below recommended Phase 2 dose) of 45 mg once a week (QW), the median overall survival among evaluable patients followed for survival was 5.4 months, compared to the expected survival of 2.5 months in patients refractory to and relapsed on standard venetoclax in combination with hypomethylating agents; In the second dose level, 60 mg, administered once a week, 3 out of 9 evaluable patients (33%) achieved an overall response defined as leukemia-free status that includes complete response (CR), complete response with incomplete hematologic recovery (CRi), and morphologic leukemia-free state (MLFS). Median survival has not been reached; In the third dose level of 30 mg twice a week, 4 out of 8 patients (50%) evaluable to date achieved overall response defined as leukemia-free status that includes complete response (CR), complete response with incomplete hematologic recovery (CRi), and morphologic leukemia-free state (MLFS). Median survival has not been reached; Observed efficacy outcomes exceeded the target ORR of 20% and mOS of 3 months; The highest response rates were observed among patients harboring ASXL1 mutations as previously reported.

Notably, responses were highly correlated with mutational status, with 6 out of 8 responding patients having myelodysplasia-related somatic mutations and 5 having specifically ASXL1 mutations; A 100% overall response rate (CR/CRi/MLFS) was achieved in patients with ASXL1 mutations in the 30 mg BIW cohort to date; Based on the preliminary findings from this Phase 2a trial, the trial has been expanded to include two additional cohorts consisting of dosing at 30 mg BIW. One cohort will enroll AML patients with ASXL1 mutations and the other AML patients with myelodysplasia-related molecular mutations other than ASXL1. Study enrollment continues and additional updates and data are expected in third quarter.

The Phase 2a clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 and 60 mg. In the 60 mg dose cohort patients were randomized into either a 60 mg dose once per week or a 30 mg dose two times per week. The target response rate at the optimal dose level is 20% with a target median survival of at least 3 months.

In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials.